ArticleFrontiers in neurology
Healthcare utilization and productivity losses associated with CIDP: results from an international survey.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), a rare autoimmune disorder affecting peripheral nerves, is associated with substantial societal costs. This study assesses healthcare utilization and productivity losses across varying levels of patient disability. Methods: Data were obtained from Adelphi's CIDP Disease Specific Programme™ (September 2022-April 2023), a digital, international, real-world survey involving neurologists and their patients (UK, France, Germany, Italy, Spain). Disability was measured using the Inflammatory Neuropathy Cause and Treatment (INCAT; range: 0-10), and categorized as mild (≤2), moderate (3-4), or severe (≥5). Neurologists provided data on treatment, informal care, hospitalizations, mobility aids, and home modifications for 542 patients, while lost productivity was reported by a subset of patients ( Results: Of the 542 patients, 236 (43.5%) had mild, 189 (34.9%) moderate, and 117 (21.6%) severe disability. Treatment rates increased with severity (receiving treatment: mild 78.4%, moderate 89.9%, severe 92.3%; Conclusion: CIDP is associated with substantial healthcare utilization that increases with increasing disability, highlighting the progressive functional decline associated with more severe disease. In addition to direct healthcare demands, CIDP imposes considerable caregiver support needs, changes in living conditions, and productivity losses. Together, these findings underscore the wide-ranging impact of CIDP and the need for comprehensive management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.